Does The Work Of The National Institute For Health And Clinical Excellence (NICE) Have Any Relevance For The United States?
The growing emphasis on evidence-based decision-making in health care, especially regarding health technologies, has generated notable debate and discussion in the U.S. around establishing a more formalized process or system for conducting comparative effectiveness research. In the eyes of many observers, this is quite similar to the health technology assessment programs existing in a number of European countries. The National Institute for Health and Clinical Excellence (NICE) in the U.K. is one the most discussed and debated systems currently in operation, since it represents one of the most sophisticated national attempts to systematically review the value, or relative costs and benefits, of various treatments. The National Pharmaceutical Council commissioned a study of NICE in order to understand its methods of working and to explore its relevance to the United States.
CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...
E.V.I.dently May 2013
Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...
Why Real-World Evidence Matters
National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...CER Collaborative: Providing the Tools for Better Formulary Decisions
National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...
NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer
WASHINGTON, DC (April 24, 2013) The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (...NPC Survey Shows Health Care Stakeholders Continue to Show Optimism About Future Role of Comparative Effectiveness Research
(Washington, DC, March 19, 2013)—As the implementation of the Affordable Care Act (ACA) picks up speed, a new survey shows that health care...National Pharmaceutical Council Welcomes Amgen as Its Newest Member
Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards
Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
The State of CER and the Environment for Health Care Decision Making
This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...Keeping Our Eye on the CER Ball
Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Living Up to Its Name? The Role of Patient-Centered Research
Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...Why Real-World Evidence Matters
National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...CER Collaborative: Assessing Evidence and Informing Decision-Making
National Pharmaceutical Council (NPC) Director of Comparative Effectiveness Research Dr. Jennifer Graff discusses an initiative designed to help...The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making
NPC discusses the findings from its third annual survey that gauges the attitudes and expectations of comparative effectiveness research (CER) among...Taking Patient Variations Into Account
Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...CER Collaborative: Providing the Tools for Better Formulary Decisions
National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...CER Tweets of the Week (Apr. 29 – May 3, 2013)
Conversations on Twitter about evidence and comparative effectiveness research highlighted the Agency for Healthcare Research and Quality’s call for...The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...Research
Pharmaceutical Benefits Under State Medical Assistance Programs, 1973
This edition of the Pharmaceutical Benefits Under St
Principles for Planning and Conducting Comparative Effectiveness Research
A group of leading researchers developed a set of 13 best practice principles that could help to...
The Current Evidence-Based Medicine Landscape
This 2008 reference guide identifies and documents all relevant organizations, activities,...- 1 of 10
- >
Commentary & Testimony
The State of CER and the Environment for Health Care Decision Making
Keeping Our Eye on the CER Ball
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
Living Up to Its Name? The Role of Patient-Centered Research
The Risks of Standardized Health Care